跳至主導覽
跳至搜尋
跳過主要內容
臺北醫學大學 首頁
說明與常見問題
English
中文
首頁
專家檔案
研究單位
專案
研究成果
資料集
活動
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
林 聖閎
主治醫師
,
衛生福利部雙和醫院
https://orcid.org/0000-0002-2602-1753
電子郵件
15318
s.tmu.edu
tw
h-index
99
引文
6
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2017
2022
每年研究成果
概覽
指紋
網路
研究成果
(13)
資料集
(6)
類似的個人檔案
(8)
指紋
查看啟用 Sheng-Hong Lin 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Pharmacology, Toxicology and Pharmaceutical Science
Sjoegren Syndrome
100%
Autoantibodies
76%
Autoimmune Disease
72%
Immunoglobulin M
68%
4 Hydroxynonenal
66%
Systemic Lupus Erythematosus
62%
Rheumatoid Arthritis
59%
Syndrome
48%
Immunoglobulin A
48%
Cohort Study
46%
Thyroiditis
37%
Complement Component C1s Inhibitor
33%
Histamine H1 Receptor Antagonist
33%
Trypsin Inhibitor
33%
Virus Hepatitis
33%
Liver Cell Carcinoma
33%
Hepatitis B Virus
33%
Hepatitis C Virus
33%
Proton Pump Inhibitor
33%
Jaw Osteonecrosis
33%
Bisphosphonic Acid Derivative
33%
Pneumocystis Jiroveci
33%
Malonaldehyde
33%
Rheumatic Disease
33%
Hepatitis C
33%
Immunoglobulin G
33%
Isoniazid
28%
Antihistaminic Agent
27%
Autoimmune Hemolytic Anemia
26%
Systemic Vasculitis
18%
Comorbidity
15%
Myasthenia gravis
15%
Ankylosing Spondylitis
15%
Dermatomyositis
13%
Polymyositis
13%
Plasma Protein
11%
Addison Disease
11%
Systemic Sclerosis
10%
Cyclophosphamide
10%
Mycophenolic Acid
10%
Immunoglobulin
9%
Complement Factor H
8%
Haptoglobin
7%
Immunosuppressive Agent
6%
Human Immunodeficiency Virus Infection
6%
Methotrexate
6%
Ciclosporin
6%
Interstitial Lung Disease
6%
Biological Product
6%
Malignant Neoplasm
6%
Immunology and Microbiology
Immunoglobulin M
77%
Autoantibodies
76%
Autoimmune Disease
72%
Sjögren's Syndrome
67%
Inflammatory Arthritis
66%
Systemic Lupus Erythematosus
62%
Immunoglobulin A
60%
Population
40%
Thyroiditis
38%
C1-Inhibitor
33%
Autoimmune Rheumatic Disease
33%
Innate Lymphoid Cell
33%
Pneumocystis Jiroveci
33%
Isotype
33%
Acetylation
28%
Autoimmune Hemolytic Anemia
27%
Vasculitis
20%
Lupus Erythematosus
16%
Ankylosing Spondylitis
16%
Myasthenia gravis
16%
Intravenous Immunoglobulin
15%
Blood Level
13%
Comorbidity
13%
Dermatomyositis
13%
Polymyositis
13%
Systemic Scleroderma
12%
Systemic Autoimmune Disease
12%
Factor H
11%
Mycophenolic Acid
10%
Cyclophosphamide
10%
Protein Acetylation
9%
Immune Response
9%
Mouth
6%
Ciclosporin
6%
Epitope
6%
Human Immunodeficiency Virus Infection
6%
Methotrexate
6%
Biological Product
6%
Random Forest
6%
Antinuclear Antibody
6%
Heavy Chain
6%
Immunity
6%
Organ-Specific Autoimmune Disease
5%
Microbiome
5%
Immune System
5%
Graves' Disease
5%
Intestine Flora
5%
Myositis
5%
Idiopathic Thrombocytopenic Purpura
5%
Medicine and Dentistry
Hazard Ratio
70%
Autoimmune Disease
66%
Rheumatoid Arthritis
40%
Biological Product
40%
Fatty Acid Metabolism
33%
Hip Replacement
33%
Ganglioglioma
33%
RNA Editing
33%
Pneumocystis Jirovecii
33%
Autoimmune Rheumatic Disease
33%
Prognostic Factor
33%
Proton-Pump Inhibitor
33%
Thymectomy
33%
Total Knee Arthroplasty
33%
Cohort Analysis
33%
Proportional Hazards Model
13%
Dermatomyositis
13%
Polymyositis
13%
Sjoegren Syndrome
12%
Population
12%
Systemic Lupus Erythematosus
10%
Cyclophosphamide
10%
Mycophenolic Acid
10%
Methotrexate
9%
Systemic Scleroderma
8%
Thyroiditis
7%
Systemic Vasculitis
7%
Cyclosporine
6%
Interstitial Lung Disease
6%
Human Immunodeficiency Virus Infection
6%
Drug Therapy
6%
Fatty Acid Oxidation
6%
Glioblastoma
6%
Isocitrate Dehydrogenase
6%
Evans Syndrome
6%
